Lesiplus (Drospirenone, Ethinylestradiol | Lactose)

Lesiplus, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent unintended pregnancy.

• Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age.
• Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.
• Reduction of ovarian cysts: may decrease the formation of functional ovarian cysts.

• Drospirenone and ethinylestradiol work together to suppress the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinizing hormone that triggers ovulation. The progestogenic component also thickens cervical mucus, creating a barrier to sperm, while the estrogen component stabilizes the endometrial lining, reducing breakthrough bleeding and enhancing contraceptive efficacy.

Lesiplus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: soreness or swelling of breast tissue.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or mood swings.
• Spotting: irregular vaginal bleeding between periods.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Hypertension: significant increase in blood pressure.
• Liver disorders: jaundice or abnormal liver function tests.
• Gallbladder disease: formation of gallstones or cholecystitis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden vision loss or retinal vein occlusion.

Before prescribing Lesiplus, clinicians should assess individual risk factors and consider contraindications.

• Smoking: avoid use in women over 35 who smoke heavily.
• Cardiovascular disease: contraindicated in patients with history of stroke, myocardial infarction, or uncontrolled hypertension.
• Liver disease: use with caution in patients with active liver disease.
• Migraine with aura: avoid in women who experience migraine headaches with visual disturbances.
• Pregnancy and lactation: not recommended during pregnancy or while breastfeeding.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lesiplus can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antiepileptic drugs (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness.
• Rifampin and other strong enzyme inducers: significantly decrease hormone levels.
• Certain antivirals (e.g., ritonavir): may lower contraceptive efficacy.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., fluconazole): may increase hormone concentrations.
• St. John’s wort: may modestly reduce contraceptive effect.
• Diuretics (e.g., thiazides): may affect fluid balance and blood pressure.